MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Kumar, Smriti ^a,b   Kumar, Arooshi ^a,b   Shah, Parag P ^a   Rai, Shesh N ^a   Panguluri, Siva K ^c   Kakar, Sham S ^a,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PROTEASOME; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; RNA ANALYSIS; UPREGULATION;

EID: 80053174012     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-17     Document Type: Article

References (43)

1. Current management strategies for ovarian cancer. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC, Mayo Clin Proc 2007 82 751 770 10.4065/82.6.751 17550756 (Pubitemid 46878099)
2. Cancer Statistics. Siegel R, Ward E, Brawley O, Jemal A, CA Cancer J Clin 2011 61 212 236 10.3322/caac.20121 21685461
3. Cancer of the ovary. Cannistra SA, N Engl J Med 2004 351 24 2519 2529 10.1056/NEJMra041842 15590954 (Pubitemid 39603165)
4. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T, Cancer Res 2008 68 2581 2586 10.1158/0008-5472.CAN-08-0088 18413725 (Pubitemid 351556255)
5. Minireview: epigenetic changes in ovarian cancer. Balch C, Fang F, Matei DE, Huang TH, Nephew KP, Endocrinology 2009 150 4003 4011 10.1210/en.2009-0404 19574400
6. How do real tumors become resistant to cisplatin? Borst P, Rottenberg S, Jonkers J, Cell Cycle 2008 7 1353 1359 10.4161/cc.7.10.5930 18418074 (Pubitemid 351872573)
7. MicroRNAs in ovarian cancer biology and therapy resistance. Van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA, Int J Biochem Cell Biol 42 1282 1290
8. Cisplatin and DNA repair in cancer chemotherapy. Zamble DB, Lippard SJ, Trends Biochem Sci 1995 20 435 439 10.1016/S0968-0004(00)89095-7 8533159
9. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Siddik ZH, Oncogene 2003 22 47 7265 7279 10.1038/sj.onc.1206933 14576837 (Pubitemid 37487159)
10. Mechanisms of resistance to cisplatin. Kartalou M, Essigmann JM, Mutat Res 2001 478 23 43 10.1016/S0027-5107(01)00141-5 11406167 (Pubitemid 32530848)
11. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N, Mol Cancer 2005 4 25 10.1186/1476-4598-4-25 16033649 (Pubitemid 41460834)
12. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S, Int J Biochem Cell Biol 42 1262 1272
13. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 2 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
14. The functions of animal microRNAs. Ambros V, Nature 2004 431 7006 350 355 10.1038/nature02871 15372042 (Pubitemid 39265675)
15. How do microRNAs regulate gene expression? Cannell IG, Kong YW, Bushell M, Biochem Soc Trans 2008 36 1224 1231 10.1042/BST0361224 19021530
16. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Calin G, Proc Natl Acad Sci USA 2002 99 15524 15529 10.1073/pnas.242606799 12434020 (Pubitemid 35403967)
17. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR, Nature 2005 435 834 838 10.1038/nature03702 15944708 (Pubitemid 40839735)
18. MicroRNA signatures in human ovarian cancer. Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu C, Alder H, Calin GA, Menard S, Croce CM, Cancer Res 2007 67 8699 8707 10.1158/0008-5472. CAN-07-1936 17875710 (Pubitemid 47437445)
19. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Taylor DD, Gercel-Taylor C, Gynecol Oncol 2008 110 13 21 10.1016/j.ygyno.2008.04.033 18589210 (Pubitemid 351853251)
20. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ, Cancer Res 2008 68 425 433 10.1158/0008-5472.CAN-07-2488 18199536 (Pubitemid 351380068)
21. RAS is regulated by the let-7 microRNA family. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ, Cell 2005 120 5 635 647 10.1016/j.cell.2005.01.014 15766527 (Pubitemid 40343076)
22. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A, Genes Chromosomes Cancer 2004 39 167 169 10.1002/gcc.10316 14695998 (Pubitemid 38056091)
23. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM, Biochem Pharmacol 2008 76 582 588 10.1016/j.bcp.2008.06.007 18619946
24. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Hamid T, Malik MT, Kakar SS, Mol Cancer 2005 4 3 10.1186/1476-4598-4-3 15649325 (Pubitemid 40230563)
25. Worldwide burden of gynaecological cancer: the size of the problem. Sankaranarayanan R, Ferlay J, Best Pract Res Clin Obstet Gynaecol 2006 20 207 225 10.1016/j.bpobgyn.2005.10.007 16359925 (Pubitemid 43380597)
26. MicroRNA and ovarian cancer. Corney DC, Nikitin AY, Histol Histopathol 2008 23 9 1161 1169 18581287
27. Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer. Shah PP, Hutchinson LE, Kakar SS, J Ovarian Res 2009 2 11 10.1186/1757-2215-2-11 19712461
28. MicroRNAs in ovarian carcinomas. Dahiya N, Morin PJ, Endocr Relat Cancer 17 77 89
29. The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Burchenal JH, Robinson E, Johnston SF, Kushida MN, Science 1950 111 116 10.1126/science.111.2875.116 15400457
30. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM, Gynecol Oncol 2009 113 249 255 10.1016/j.ygyno.2009.01.014 19237188
31. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H, Gynecol Oncol 2009 114 253 259 10.1016/j.ygyno.2009.04.024 19446316
32. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, Mankaruous M, Gabril M, Girgis A, Yousef GM, Br J Cancer 102 1244 1253
33. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Butzow R, Croce CM, Coukos G, Zhang L, Cancer Res 2008 68 10307 10314 10.1158/0008-5472.CAN-08-1954 19074899
34. Role of microRNAs in drug resistant ovarian cancer cells. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C, Gynecol Oncol 2008 111 478 486 10.1016/j.ygyno.2008.08.017 18823650
35. Cellular processing of platinum anticancer drugs. Wang D, Lippard SJ, Nat Rev Drug Discov 2005 4 307 320 10.1038/nrd1691 15789122 (Pubitemid 41130944)
36. Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS, Cancer Res 2006 66 8870 8877 10.1158/0008-5472.CAN-06-1280 16951204 (Pubitemid 44449205)
37. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS, J Biol Chem 2000 275 30907 15 10906123
38. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano MD, Pío R, Gil-Bazo I, Rouzaut A, Mol Cancer 2010 9 130 10.1186/1476-4598-9-130 20509890
39. Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I, Acta Bioch Polonica 2003 50 2 497 508 (Pubitemid 37034702)
40. Mare's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway. Xu S, Xue C, Li J, Bi Y, Cao Y, J Viral 2011 85 276 85 10.1128/JVI.01392-10
41. Multiple E2F-Induced MicroRNAs Prevent Replicative Stress in Response to Mitogenic Signaling. Buenos MJ, Gomez de Cordon M, Laresgoiti U, Fernández-Piqueras J, Zubiaga AM, Malumbres, Mol Cell Biol 2010 30 2983 2995 10.1128/MCB.01372-09 20404092
42. p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. Wei J, Zhao J, Long M, Han Y, Wang X, Lin F, Ren J, He T, Zhang H, BMC Cancer 2010 10 632 10.1186/1471-2407-10-632 21087528
43. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. Parker RJ, Eastman A, Bostick-Bruton F, Reed E, J Clin Invest 1991 87 772 777 10.1172/JCI115080 1999494